TITRE | (EN) A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma |
PROTOCOLE ID | FIERCE-HN |
CLINICAL TRIAL.gov ID | NCT06064877 |
TYPE(S) DE CANCER | ORL |
PHASE | Phase III |
TYPE D'ÉTUDE | Clinique |
INSTITUTION |
CUSM
1001 boul. Décarie |
VILLE | Montréal |
INVESTIGATEUR(RICE) PRINCIPAL(E) | Nathaniel Bouganim |
COORDONATEUR(RICE) |
Julie Latreille julie.latreille@muhc.mcgill.ca 514-934-1934 poste 38945 |
STATUT | Actif en recrutement |
CRITÈRES D'ÉLIGIBILITÉ | (EN)
|
CRITÈRES D'EXCLUSION | (EN)
A full list of inclusion and exclusion criteria can be found in the protocol. |